Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ImmunityBio (IBRX) has provided an announcement.
ImmunityBio, Inc. recently announced that the FDA approved its Anktiva® drug for a specific type of bladder cancer, signaling a potential breakthrough in treatment options. Additionally, the company is contemplating a significant expansion of its 2015 Equity Incentive Plan, proposing to increase the authorized shares for issuance by nearly 20 million, a decision pending stockholder vote at the upcoming annual meeting. This news could influence the company’s stock performance, as it reflects both a critical regulatory milestone and a strategic corporate development.
See more insights into IBRX stock on TipRanks’ Stock Analysis page.